AI Article Synopsis

  • - This study examines the effects of repetitive transcranial magnetic stimulation (rTMS) on patients with treatment-resistant depression (TRD), focusing on the role of soluble TREM2, a protein linked to inflammation and microglial activity.
  • - Results showed that rTMS improved depressive symptoms and cognitive function in the participants, but did not change serum levels of sTREM2, suggesting it may not play a role in rTMS's therapeutic effects.
  • - The authors recommend further research with larger samples and different methods to better understand the relationship between rTMS and sTREM2 in depression treatment.

Article Abstract

Aim: Repetitive transcranial magnetic stimulation (rTMS) is one of the most effective and minimally invasive treatments for treatment-resistant depression (TRD). However, the mechanism underlying the therapeutic effects of rTMS in patients with TRD remains unclear. In recent years, the pathogenesis of depression has been closely associated with chronic inflammation and microglia are believed to play an important role in chronic inflammation. Triggering receptor expressed on myeloid cells-2 (TREM2) plays an important role in microglial neuroinflammatory regulation. In this study, we investigated the changes in peripheral soluble TREM2 (sTREM2) before and after rTMS treatment in patients with TRD.

Methods: Twenty-six patients with TRD were enrolled in this frequency (10 Hz) rTMS study. Depressive symptoms, cognitive function, and serum sTREM2 concentrations were measured at baseline and the end of the 6-week rTMS treatment.

Results: This study showed that rTMS ameliorated depressive symptoms and partially improved cognitive dysfunction in TRD. However, rTMS treatment did not alter serum sTREM2 levels.

Conclusions: This is the first sTREM2 study in patients with TRD who underwent rTMS treatment. These results suggest that serum sTREM2 may not be relevant for the mechanism underlying the therapeutic effect of rTMS in patients with TRD. Future studies should confirm the present findings using a larger patient sample and a sham rTMS procedure, as well as CSF sTREM2. Furthermore, a longitudinal study should be conducted to clarify the effects of rTMS on sTREM2 levels.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275288PMC
http://dx.doi.org/10.1002/npr2.12332DOI Listing

Publication Analysis

Top Keywords

patients trd
16
rtms
12
rtms patients
12
rtms treatment
12
serum strem2
12
triggering receptor
8
receptor expressed
8
expressed myeloid
8
myeloid cells-2
8
treatment-resistant depression
8

Similar Publications

Objectives: A combination of chemotherapy and radiotherapy is employed in the curative and postoperative treatment of locally advanced head and neck cancers (HNC). Integrated chemoradiation (CRT) treatments result in a non-negligible rate of severe toxic effects. Treatment-related death (TRD) is a crucial topic for physicians involved in the curative treatment of HNC.

View Article and Find Full Text PDF

EEG alpha activity as predictor for TBS-rTMS treatment outcome in depression.

J Psychiatr Res

January 2025

Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Psychiatry, Zürich, Lenggstrasse 31, P.O. Box 363, 8032, Zürich, Switzerland.

Repetitive transcranial magnetic stimulation (rTMS) is an established psychiatric procedure for patients suffering from treatment-resistant depression (TRD). Biomarker identification to predict rTMS outcomes may assist the clinician in optimizing treatment selection. In recent years, different electrophysiological markers, in particular electroencephalographic (EEG) markers, were shown to yield discriminative power between responders and non-responders to various TRD treatments.

View Article and Find Full Text PDF

Objectives: Electroconvulsive therapy (ECT) is one of the most effective treatments for treatment-resistant depression (TRD), even though the molecular mechanisms underlying its efficacy remain largely unclear. This study aimed, for the first time, to analyze plasma levels of miRNAs, key regulators of gene expression, in TRD patients undergoing ECT to investigate potential changes during treatment and their associations with symptom improvement.

Methods: The study involved 27 TRD patients who underwent ECT.

View Article and Find Full Text PDF

Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening systemic hyperinflammatory syndrome, rarely associated with bone marrow failure (BMF). Telomere biology disorders (TBD) are caused by inherited defects in telomerase processes and can have heterogeneous presentations including idiopathic pulmonary fibrosis, cirrhosis, and BMF. We report a case of a 10-year-old male from Lima, Peru, who presented with HLH as the initial manifestation of a TBD.

View Article and Find Full Text PDF

Rectangular Repetitive Transcranial Magnetic Monophasic vs Biphasic Stimulation for Major Depressive Disorder: A Randomized Controlled Pilot Trial.

Neuromodulation

January 2025

Department of Psychiatry and Behavioral Sciences, Division of Child and Adolescent Psychiatry, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.

Objectives: Biphasic sinusoidal repetitive transcranial magnetic stimulation (rTMS) is a noninvasive brain stimulation treatment that has been approved by the US Food and Drug Administration for treatment-resistant depression (TRD). Recent advances suggest that standard rTMS may be improved by altering the pulse shape; however, there is a paucity of research investigating pulse shape, owing primarily to the technologic limitations of currently available devices. This pilot study examined the feasibility, tolerability, and preliminary efficacy of biphasic and monophasic rectangular rTMS for TRD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!